ETON vs. QTTB, YS, IOBT, PRPH, ANVS, ANIX, MIST, CLSD, BRNS, and GNLX
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Q32 Bio (QTTB), YS Biopharma (YS), IO Biotech (IOBT), ProPhase Labs (PRPH), Annovis Bio (ANVS), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), Clearside Biomedical (CLSD), Barinthus Biotherapeutics (BRNS), and Genelux (GNLX). These companies are all part of the "pharmaceutical preparations" industry.
Q32 Bio (NASDAQ:QTTB) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
Eton Pharmaceuticals has a net margin of 2.66% compared to Eton Pharmaceuticals' net margin of 0.00%. Q32 Bio's return on equity of 5.65% beat Eton Pharmaceuticals' return on equity.
In the previous week, Q32 Bio's average media sentiment score of 0.96 beat Eton Pharmaceuticals' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.
Q32 Bio currently has a consensus target price of $47.50, suggesting a potential upside of 56.46%. Eton Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 148.62%. Given Q32 Bio's higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Q32 Bio.
Eton Pharmaceuticals has higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eton Pharmaceuticals received 82 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 100.00% of users gave Q32 Bio an outperform vote while only 62.22% of users gave Eton Pharmaceuticals an outperform vote.
31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 16.1% of Q32 Bio shares are owned by company insiders. Comparatively, 13.2% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Q32 Bio has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Summary
Eton Pharmaceuticals beats Q32 Bio on 11 of the 15 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
